References
- Andersen K. W., Mouridsen H. T., Castberg T., et al. Organization of the Danish adjuvant trials in breast cancer. Dan. Med. Bull. 1981; 28: 102
- Baum M. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet 1985; I: 836
- Baum M., Brinkley D. M., Dossett J.A., et al. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet 1983; I: 257
- Consensus Development Conference Report. Adjuvant chemotherapy for breast cancer. JAMA 1985; 254: 3461
- EORTC Breast Cancer Cooperative Group. Revision of standards for the assessment of hormone receptor in human breast cancer. Report of the second EORTC Workshop. Eur. J. Cancer 1980; 16: 1513
- Goldhirsch A., Gelber R. D., Mouridsen H. Endocrine aspects in adjuvant therapy for early breast cancer. Endocrine mechanism and treatment for breast cancer. Endocrine therapy of breast cancer, F. Cavalli. Springer Verlag. 1986; 91
- Koenders A., Thorpe S. M., on behalf of the EORTC receptor group. Standardization of steroid receptor assays in human breast cancer. I. Reproducibility of estradiol and progesterone receptor assays. Eur. J. Cancer Clin. Oncol. 1983; 19: 1221
- Ludwig Breast Cancer Study Group. Randomized trial of chemo-endocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984; I: 1256
- Meeting Report London 1984. Review of mortality results in randomized trials in early breast cancer. Lancet 1984; II: 1205
- Mouridsen H. T. Anti-hormones in primary breast cancer. A review. Rev. Endocr. Rel. Cancer 1985; 17: 81
- Mouridsen H. T., Rose C. Attempting to understand differences between the results of the main trials of adjuvant tamoxifen in primary breast cancer. Progress in cancer research and treatment, vol. 35. Hormones and cancer 3, F. Bresciani, R. J. B. King, M. E. Lippman, J.-P. Reynaud. Raven Press, New York 1988; 417
- Pritchard K. I., Meakin J. W., Boyd N.F., . A prospective randomized controlled trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. Adjuvant therapy of cancer IV, S. E Jones, S. E. Salmon, et al. Grune & Stratton, Orlando 1984; 339
- Ribeiro G., Palmer M. K. Adjuvant tamoxifen for operable carcinoma of the breast. Report of clinical trial by the Christie Hospital and Holt Radium Institute. Br. Med. J. 1983; 286: 827
- Ribeiro G., Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma—7-yr results. Eur. J. Cancer Clin. Oncol. 1985; 21: 897
- Rose C., Mouridsen H. T., Thorpe S.M., et al. Antiestrogen treatment of postmenopausal breast cancer patients with high risk of recurrence. 72 months of life-table analysis and steroid hormone receptor status. World J. Surg. 1985; 9: 765
- Rose C., Thorpe S. M., Mouridsen H.T., et al. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. 36 months of life-table analysis and steroid hormone receptor status. Breast Cancer Res. Treat. 1983; 3: 77
- Schart R. W., Tarloni H. Histological typing of breast tumors. World Health Organization, Geneva 1968
- Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer. The Scottish Trial. Lancet 1987; II: 171
- Wallgren A. Treatment with nolvadex alone and in combination with chemotherapy in postmenopausal women. Rev. Endocr. Rel. Cancer (Suppl). 1982; 12: 15
- Wallgren A., Baral E., Castensen J., . Should adjuvant therapy be given for several years in breast cancer?. Adjuvant Therapy of Cancer IV, S. E Jones, S. E. Salmon, et al. Grune & Stratton. 1984; 331